Biopharmaceutical company AbbVie, Inc. (NYSE: ABBV) announced fourth-quarter 2024 financial results, reporting a double-digit dip in adjusted earnings and an increase in revenues. The company reported worldwide net revenues of $15.1 billion for the December quarter, up 6% from the corresponding period of 2023. The main operating segments registered growth. Net income, adjusted for special […]
“Biopharmaceutical company AbbVie, Inc. (NYSE: ABBV) announced fourth-quarter 2024 financial results, reporting a double-digit dip in adjusted earnings and an increase in revenues. The company reported worldwide net revenues of $15.1 billion for the December quarter, up 6% from the corresponding period of 2023. The main operating segments registered growth. Net income, adjusted for special […]
· January 31, 2025
Biopharmaceutical company AbbVie, Inc. (NYSE: ABBV) announced fourth-quarter 2024 financial results, reporting a double-digit dip in adjusted earnings and an increase in revenues.
The company reported worldwide net revenues of $15.1 billion for the December quarter, up 6% from the corresponding period of 2023. The main operating segments registered growth.
Net income, adjusted for special items, declined to $2.16 per share in Q4 from $2.79 per share in the year-ago quarter. On a reported basis, it was a net loss of $22 million or $0.02 per share in the fourth quarter, compared to a profit of $822 million or $0.46 per share last year.
